Celldex Therapeutics (CLDX) Stock Forecast & Price Target

$33.20

+0.34 (+1.03%)

(As of 09/27/2024 ET)

Celldex Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
1

Buy
6

Based on 7 Wall Street analysts who have issued ratings for Celldex Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 1 has given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for CLDX.

Consensus Price Target

$63.83
92.27% Upside

According to the 7 analysts' twelve-month price targets for Celldex Therapeutics, the average price target is $63.83. The highest price target for CLDX is $90.00, while the lowest price target for CLDX is $37.00. The average price target represents a forecasted upside of 92.27% from the current price of $33.20.

CLDX Analyst Ratings Over Time

Type	Current Forecast 9/29/23 to 9/28/24	1 Month Ago 8/30/23 to 8/29/24	3 Months Ago 7/1/23 to 6/30/24	1 Year Ago 9/29/22 to 9/29/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$63.83	$63.83	$62.17	$63.33
Forecasted Upside	92.27% Upside	59.86% Upside	67.97% Upside	130.14% Upside
Consensus Rating	Buy	Moderate Buy	Moderate Buy	Moderate Buy

Retire off just one stock ticker? (Ad)

ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...

Click here for the ticker >>>

CLDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CLDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Celldex Therapeutics Stock vs. The Competition

Type	Celldex Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.78	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	92.27% Upside	818.62% Upside	6.14% Upside
News Sentiment Rating	Neutral News See Recent CLDX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/27/2024	Wolfe Research 3 of 5 stars	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
9/26/2024	Wells Fargo & Company 3 of 5 stars	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/26/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00	+122.10%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00	+52.83%
6/18/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$58.00	+66.14%
2/27/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$72.00 ➝ $90.00	+75.06%
NOTICE: You have until Tuesday, November 19th (Ad) On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy... Click here for the ticker >>>
12/20/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:07 PM ET.

CLDX Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Celldex Therapeutics is $63.83, with a high forecast of $90.00 and a low forecast of $37.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There is currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CLDX shares.
: According to analysts, Celldex Therapeutics's stock has a predicted upside of 92.27% based on their 12-month stock forecasts.
: Over the previous 90 days, Celldex Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.
: Celldex Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Celldex Therapeutics more than other "medical" companies. The consensus rating for Celldex Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CLDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Massive NVIDIA Sell-Off: Are We Headed for a Market Collapse? (Ad)

You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this year. But here's what's even more concerning...

Click here for his urgent warning - and 4 steps you need to take today to protect your retirement to

This page (NASDAQ:CLDX) was last updated on 9/28/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Celldex Therapeutics (CLDX) Stock Forecast & Price Target